Trials / Recruiting
RecruitingNCT05430828
Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,000 (estimated)
- Sponsor
- Federico II University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Repatha (evolocumab); Praluent (alirocumab) | Dosage form: Injection |
Timeline
- Start date
- 2020-03-07
- Primary completion
- 2022-01-30
- Completion
- 2030-03-31
- First posted
- 2022-06-24
- Last updated
- 2026-01-22
Locations
27 sites across 1 country: Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05430828. Inclusion in this directory is not an endorsement.